Canaccord Genuity analyst Sumant Kulkarni maintained a Buy rating on Cortexyme (NASDAQ:CRTX) Inc on Friday, setting a price target of $75, which is approximately 78.57% above the present share price of $42.
Kulkarni expects Cortexyme Inc to post earnings per share (EPS) of -$0.61 for the third quarter of 2020.
The current consensus among 4 TipRanks analysts is for a Strong Buy rating of shares in Cortexyme, with an average price target of $98.5.
The analysts price targets range from a high of $184 to a low of $59.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $0 and a net profit of -$17.86 million. The company's market cap is $1.24 billion.
According to TipRanks.com, Canaccord Genuity analyst Sumant Kulkarni is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 15.6% and a 46.11% success rate.
Cortexyme, Inc. is a biopharmaceutical company, which develops therapeutics based on data supporting a new theory of the cause of Alzheimer's and other neurodegenerative disorders. Its product, COR388, is in clinical trial. The company was founded by Casey Crawford Lynch, Stephen Dominy, and Kristen Gafric on June 20, 2012 and is headquartered in South San Francisco, CA.